Phase 3, multicentre, randomised, placebo-controlled study evaluating the efficacy and safety of ustekinumab in patients with systemic lupus erythematosus

por van Vollenhoven, Ronald F, Kalunian, Kenneth C, Dörner, Thomas, Hahn, Bevra H, Tanaka, Yoshiya, Gordon, Robert M, Shu, Cathye, Fei, Kaiyin, Gao, Sheng, Seridi, Loqmane, Gallagher, Patrick, Lo, Kim Hung, Berry, Pamela, Zuraw, Qing C
Publicado 2022

Guselkumab, an inhibitor of the IL-23p19 subunit, provides sustained improvement in signs and symptoms of active psoriatic arthritis: 1 year results of a phase III randomised study...

por Ritchlin, Christopher T, Helliwell, Philip S, Boehncke, Wolf-Henning, Soriano, Enrique R, Hsia, Elizabeth C, Kollmeier, Alexa P, Chakravarty, Soumya D, Zazzetti, Federico, Subramanian, Ramanand A, Xu, Xie L, Zuraw, Qing C, Sheng, Shihong, Jiang, Yusang, Agarwal, Prasheen, Zhou, Bei, Zhuang, Yanli, Shawi, May, Karyekar, Chetan S, Deodhar, Atul
Publicado 2021